For research use only. Not for therapeutic Use.
Teclistamab（Cat No.:I042204）is a bispecific monoclonal antibody designed to target two proteins: CD3 on T-cells and BCMA (B-cell maturation antigen) on multiple myeloma cells. By engaging T-cells through CD3 and directing them to BCMA-expressing cancer cells, teclistamab aims to trigger a potent immune response to specifically target and destroy myeloma cells. It is being studied in clinical trials for the treatment of relapsed or refractory multiple myeloma. The drug’s potential lies in its ability to enhance immune system activity, offering a promising treatment option for patients with this challenging disease.
| Catalog Number | I042204 |
| CAS Number | 2119595-80-9 |
| Purity | ≥95% |
